The US Food and Drug Administration has granted approval to a new therapy developed by Jazz Pharmaceuticals targeting a rare form of brain tumor. This regulatory milestone provides a novel treatment option for patients with limited alternatives, potentially addressing an unmet medical need in neuro-oncology. The approval underscores Jazz Pharma's growing portfolio in specialty oncology therapeutics.